undamentalytics Newsletter
Sign in

Monte Rosa Therapeutics, Inc. income statement

In fiscal 2025, Monte Rosa Therapeutics, Inc. reported revenue of $124m, up 63.5% on the year before, operating income of −$54.2m (a -43.8% margin) and net income of −$38.6m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue07612429
Research and development111122142171
General and administrative32353640
Operating income−143−81−54−182
Income before tax−135−70−40−164
Income tax03−1−3
Net income−135−73−39−161
Diluted EPS———−$1.75
Diluted shares (average)51m74m83m92m
EBITDA−137−73−46−174

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: GLUE vs TNXPARCT vs GLUEGLUE vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Monte Rosa Therapeutics, Inc.